Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.35 |
| ▸ | NPC1 | O15118 | 7/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.34 |
| ▸ | RELA | Q04206 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035284 | 0.75 | MAPT (0.49) | RAB9ANPC1SMN1; SMN2THRBNPSR1 | |
| SCHEMBL4298747 | 0.73 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL13971212 | 0.68 | — | — | |
| SCHEMBL3043862 | 0.68 | TLR7 (0.34) | RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL3040193 | 0.68 | KMT2A (0.38) | SMN1; SMN2ALDH1A1MAPTCYP1A2CYP2C19 | |
| SCHEMBL19435589 | 0.65 | KDM4E (0.41) | RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL5577241 | 0.65 | KDM4E (0.41) | RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL435144 | 0.64 | KDM4E (0.44) | RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL31734268 | 0.64 | KDM4E (0.44) | RAB9ANPC1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL21875055 | 0.63 | KMT2A (0.45) | RAB9AALDH1A1LMNAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170872-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | Sanofi-Aventis U.S. LLC (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | claimed |
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SANOFI-AVENTIS U.S. LLC (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SANOFI-AVENTIS U.S. LLC (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SANOFI-AVENTIS U.S. LLC (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2170872-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | Sanofi-Aventis U.S. LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009006066-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174088-A1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOL THIENYLAMINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL AS SODIUM/PROTON EXCHANGER TYPE 3 INHIBITORS | SLC9A3, NHERF1, SLC9A5 | RAB9A 1355/4885NPC1 133/4885SMN1; SMN2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.